Research and Markets: Novel Drugs to Drive Arthritis Market Wall Street Journal (press release) Other well-established therapies have also been allowed to keep their patents, including second-line RA treatment Actemra. However, patents are due to expire during the forecast period for major drugs such as Rituxan (Rituximab), Remicade (Infliximab), ... |
